scispace - formally typeset
R

Raymond L. Hintz

Researcher at Veterans Health Administration

Publications -  30
Citations -  3035

Raymond L. Hintz is an academic researcher from Veterans Health Administration. The author has contributed to research in topics: Insulin & Insulin-like growth factor. The author has an hindex of 22, co-authored 30 publications receiving 2996 citations. Previous affiliations of Raymond L. Hintz include Baylor College of Medicine & Stanford University.

Papers
More filters
Journal ArticleDOI

Effects of short term administration of recombinant human growth hormone to elderly people.

TL;DR: It is indicated that rhGH requires further study as a potential agent for attenuating or reversing the loss of muscle and bone in elderly people.
Journal ArticleDOI

Insulin-like growth factor (IGF) binding protein complementary deoxyribonucleic acid from human HEP G2 hepatoma cells: predicted protein sequence suggests an IGF binding domain different from those of the IGF-I and IGF-II receptors.

TL;DR: Comparison of full-length protein sequences for the IGF-I and IGF-II receptors with that of the HEP G2 IGF binding protein fails to demonstrate any significant similarities among these three proteins, and suggests that each contains a unique binding domain forThe IGF peptides.
Journal ArticleDOI

Effect of recombinant human growth hormone on the muscle strength response to resistance exercise in elderly men.

TL;DR: It is suggested that deficits in GH secretion do not underlie the time-dependent leveling off of muscle strength seen with training in the elderly and provide no support for the popular view of GH as an ergogenic aid.
Journal ArticleDOI

Effects of recombinant human growth hormone on metabolic indices, body composition, and bone turnover in healthy elderly women

TL;DR: RhGH dramatically increased markers of bone turnover, with more pronounced effects in minus estrogen women, and did not alter blood pressure or circulating L-T4 levels, but a transient increase in serum T3 was observed in the minus estrogen group at 3 months.